Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 16/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.43 |
| ▸ | FLT3 | P36888 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13216971 | 0.84 | BRAF (0.44) | BRAFMAPK14 | |
| SCHEMBL2962732 | 0.83 | BRAF (0.59) | BRAFMAPK14 | |
| SCHEMBL15172107 | 0.82 | DYRK1A (0.38) | BRAFMAPK14DYRK1A | |
| SCHEMBL13940847 | 0.81 | BRAF (0.48) | BRAFMAPK14 | |
| SCHEMBL8236132 | 0.81 | BRAF (0.56) | BRAFMAPK14 | |
| SCHEMBL8228308 | 0.81 | BRAF (0.39) | BRAFMAPK14DYRK1A | |
| SCHEMBL8232601 | 0.81 | BRAF (0.48) | BRAFMAPK14DYRK1A | |
| SCHEMBL8226709 | 0.81 | BRAF (0.37) | BRAFMAPK14DYRK1A | |
| SCHEMBL12850039 | 0.78 | LMNA (0.43) | BRAFMAPK14DYRK1A | |
| SCHEMBL8229330 | 0.78 | BRAF (0.53) | BRAFMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49556-E1 | Compounds and compositions as protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-06-20 | — | — | US | claimed |
| US-8501758-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2013-08-06 | — | — | US | claimed |
| CN-102725283-A | Compounds and compositions as protein kinase inhibitors | IRM LLC | 2012-10-10 | — | — | CN | claimed |
| EP-2470526-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2012-07-04 | — | — | EP | claimed |
| US-20110306625-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-12-15 | — | — | US | claimed |
| WO-2011025927-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2011-03-03 | — | — | WO | claimed |
| US-RE49556-E1 | Compounds and compositions as protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-20230116233-A1 | Compounds And Compositions As Protein Kinase Inhibitors | ARRAY BIOPHARMA INC (US) | 2023-04-13 | — | — | US | disclosed |
| US-20200323852-A1 | Compounds And Compositions As Protein Kinase Inhibitors | IRM LLC (BM) | 2020-10-15 | — | — | US | disclosed |
| US-10576080-B2 | Compounds and compositions as protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2020-03-03 | — | — | US | disclosed |
| US-10568884-B2 | Compounds and compositions as protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-20180297986-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2018-10-18 | — | — | US | disclosed |
| US-20180297985-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2018-10-18 | — | — | US | disclosed |
| EP-2727918-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2014-05-07 | — | — | EP | disclosed |
| US-20130296318-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2013-11-07 | — | — | US | disclosed |
| US-8501758-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2013-08-06 | — | — | US | disclosed |
| CN-102725283-A | Compounds and compositions as protein kinase inhibitors | IRM LLC | 2012-10-10 | — | — | CN | disclosed |
| EP-2470526-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2012-07-04 | — | — | EP | disclosed |
| US-20110306625-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-12-15 | — | — | US | disclosed |
| WO-2011025927-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200323852-A1 | Compounds And Compositions As Protein Kinase Inhibitors | BRAF, RAF1, ARAF | BRAF 1/4885MAPK14 200/4885DYRK1A 1889/4885 |
| US-20110306625-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | BRAF, RAF1, ARAF | BRAF 1/4885MAPK14 200/4885DYRK1A 1889/4885 |
| US-20130296318-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | BRAF, RAF1, ARAF | BRAF 1/4885MAPK14 200/4885DYRK1A 1889/4885 |
| US-10568884-B2 | Compounds and compositions as protein kinase inhibitors | BRAF, RAF1, ARAF | BRAF 1/4885MAPK14 200/4885DYRK1A 1889/4885 |
| US-20180297985-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | BRAF, RAF1, ARAF | BRAF 1/4885MAPK14 200/4885DYRK1A 1889/4885 |
| US-20230116233-A1 | Compounds And Compositions As Protein Kinase Inhibitors | BRAF, RAF1, ARAF | BRAF 1/4885MAPK14 200/4885DYRK1A 1889/4885 |
| US-20180297986-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | BRAF, RAF1, ARAF | BRAF 1/4885MAPK14 200/4885DYRK1A 1889/4885 |
| US-10576080-B2 | Compounds and compositions as protein kinase inhibitors | BRAF, RAF1, ARAF | BRAF 1/4885MAPK14 200/4885DYRK1A 1889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.